Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
SK Bioscience Co. Ltd. has three pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to three examiners and two art units, showing that the portfolio has separate examiner relationships within a more limited number of technical settings. DUFFY, PATRICIA ANN is the busiest examiner, with one pending matter.
Counsel should coordinate technical positions across the two art units while reviewing each examiner’s action independently. The allocation does not support a single uniform response strategy, because examiner assignments differ. A structured docket review can preserve consistency in biotechnology and pharmaceutical disclosures while allowing claim amendments to reflect each examination channel.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576816 | METHOD FOR PRODUCING REASSORTANT REOVIRIDAE VIRUS, AND VECTOR LIBRARY FOR SAME | BLUMEL, BENJAMIN P | — |
| 18562030 | METHOD FOR PREPARING REASSORTANT ROTAVIRUS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294013 | METHOD FOR STABLY MAINTAINING POLY(A) TAIL | DUFFY, PATRICIA ANN | — |
| 18576816 | METHOD FOR PRODUCING REASSORTANT REOVIRIDAE VIRUS, AND VECTOR LIBRARY FOR SAME | BLUMEL, BENJAMIN P | — |
| 18562030 | METHOD FOR PREPARING REASSORTANT ROTAVIRUS | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294013 | METHOD FOR STABLY MAINTAINING POLY(A) TAIL | DUFFY, PATRICIA ANN | 1645 | §103 | Final Rejection | — | Pending | Jan 31, 2024 |
| 18576816 | METHOD FOR PRODUCING REASSORTANT REOVIRIDAE VIRUS, AND VECTOR LIBRARY FOR SAME | BLUMEL, BENJAMIN P | 1671 | §102§103§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18562030 | METHOD FOR PREPARING REASSORTANT ROTAVIRUS | SIFFORD, JEFFREY MARK | 1671 | §102§103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSK Bioscience Co. Ltd. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Patricia Ann Duffy has the most, with 1 of SK Bioscience Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
